Drug intelligence / Profile preview

TB-B002D

Development stage: Unknown
Lead developer: Shenzhen Turier Biotech

Overview

TB-B002D is an investigational drug candidate being developed by Shenzhen Turier Biotech for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Currently in Phase 1 clinical development, the specific modality and molecular target of TB-B002D have not been publicly disclosed. The developer, Shenzhen Turier Biotech, focuses on therapeutic areas including organ fibrosis, infectious diseases, and anti-inflammatory conditions.

Beyond the preview

Go deeper on TB-B002D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-B002D.

Explore the full profile